A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors

Study Number

3450823

Phase

I/II

Age Group

Adult

Principal Investigator

Emese Zsiros

Purpose

This is an open-label, non-randomized, Phase 1b/2 study to determine the safety and tolerability of NC410 when combined with a standard dose of pembrolizumab. This study will also assess the clinical benefit of combination therapy in participants with advanced unresectable and/or metastatic ICI refractory solid tumors OR ICI naïve MSS/MSI-low solid tumors

Check your eligibility for this trial

Check now

Full Title

A Phase 1b/2, Open-Label, Safety, Tolerability And Efficacy Study Of NC410 Plus Pembrolizumab For Participants With Advanced Unresectable And/Or Metastatic Immune Checkpoint Inhibitor (ICI) Refractory Solid Tumors Or ICI Naïve MSS/MSI-Low Solid Tumors

ClinicalTrials.Gov ID

NCT05572684

Get more information and eligibility criteria for this trial at ClinicalTrials.gov

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.